Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Die Folgen des Klimwandels haben einen direkten Einfluss auf die Primärversorgung in Deutschland: Hitzeschutz insbesondere bei älteren Patienten, die Zunahme von Infektionen und die Verlängerung der Allergiesesaison spielen medizinisch eine bedeutsame Rolle. Aber auch in der Prävention und der Aufklärung der Patienten kommt den Hausärztinnen und -ärzten eine besondere Rolle zu. Direkt aus der Praxis berichtet im Live-Webinar am 13. Mai von 18 bis 19 Uhr unser Experte Dr. med. Robin Maitra.
Erweiterte Suche
Anmelden
nach oben
Cardiovascular Drugs and Therapy
Erschienen in: Cardiovascular Drugs and Therapy 2/2016

16.01.2016 | REVIEW ARTICLE

Contrast-Induced Acute Kidney Injury: An Update

verfasst von: George Chalikias, Ioannis Drosos, Dimitrios N. Tziakas

Erschienen in: Cardiovascular Drugs and Therapy | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Abstract

Contrast-induced acute kidney injury (CI-AKI) is defined as an abrupt deterioration in renal function associated with the administration of iodinated contrast media. This type of acute kidney injury is frequently encountered as a complication of percutaneous coronary intervention (PCI) and is associated with adverse short- and long-term outcomes including mainly mortality, cardiovascular morbidity and prolongation of hospitalization. The incidence of CI-AKI after PCI ranges from 2 to 20 % according to baseline kidney function. It may also range according to the clinical setting, being higher after emergency PCI. The primary manifestation is a small decline in kidney function, occurring 1 to 3 days after the procedure. Kidney function usually returns to preexisting levels within 7 days. Incidence of acute renal failure requiring dialysis following PCI is rare (<1 %). The present article aims to review up-to-date published data concerning diagnosis, definition, epidemiology and prognosis of this novel in-hospital epidemic.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Laville M, Juillard L. Contrast-induced acute kidney injury: how should at-risk patients be identified and managed? Am J Nephrol. 2010;23(4):387–98.
2.
3.
Blackman DJ, Pinto R, Ross JR, Seidelin PH, Ing D, Jackevicius C, et al. Impact of renal insufficiency on outcome after contemporary percutaneous coronary intervention. Am Heart J. 2006;151(1):146–52.PubMedCrossRef
4.
Lindsay J, Apple S, Pinnow EE, Gevorkian N, Gruberg L, Satler LF, et al. Percutaneous coronary intervention-associated nephropathy foreshadows increased risk of late adverse events in patients with normal baseline serum creatinine. Catheter Cardiovasc Interv. 2003;59(3):338–43.PubMedCrossRef
5.
McCullough PA, Adam A, Becker CR, Davidson C, Lameire N, Stacul F, et al. Epidemiology and prognostic implications of contrast-induced nephropathy. Am J Cardiol. 2006;98(6a):5k–13k.PubMedCrossRef
6.
Rihal CS, Textor SC, Grill DE, Berger PB, Ting HH, Best PJ, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation. 2002;105(19):2259–64.PubMedCrossRef
7.
Hou SH, Bushinsky DA, Wish JB, Cohen JJ, Harrington JT. Hospital-acquired renal insufficiency: a prospective study. Am J Med. 1983;74(2):243–8.PubMedCrossRef
8.
McCullough PA, Wolyn R, Rocher LL, Levin RN, O'Neill WW. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med. 1997;103(5):368–75.PubMedCrossRef
9.
Chong E, Poh KK, Liang S, Soon CY, Tan HC. Comparison of risks and clinical predictors of contrast-induced nephropathy in patients undergoing emergency versus nonemergency percutaneous coronary interventions. J Interv Cardiol. 2010;23(5):451–9.PubMedCrossRef
10.
Nash K, Hafeez A, Hou S. Hospital-acquired renal insufficiency. Am J Kidney Dis. 2002;39(5):930–6.PubMedCrossRef
11.
Gruberg L, Mehran R, Dangas G, Mintz GS, Waksman R, Kent KM, et al. Acute renal failure requiring dialysis after percutaneous coronary interventions. Catheter Cardiovasc Interv. 2001;52(4):409–16.PubMedCrossRef
12.
Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, et al. Heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation. 2014;129(3):e28–e292.PubMedCrossRef
13.
Bartorelli AL, Marenzi G. Contrast-induced nephropathy. J Interv Cardiol. 2008;21(1):74–85.PubMedCrossRef
14.
Barrett BJ, Parfrey PS. Clinical practice. Preventing nephropathy induced by contrast medium. N Engl J Med. 2006;354(4):379–86.PubMedCrossRef
15.
Guitterez NV, Diaz A, Timmis GC, O'Neill WW, Stevens MA, Sandberg KR, et al. Determinants of serum creatinine trajectory in acute contrast nephropathy. J Interv Cardiol. 2002;15(5):349–54.PubMedCrossRef
16.
Finn WF. The clinical and renal consequences of contrast-induced nephropathy. Nephrol Dial Transplant. 2006;21(6):i2–10.PubMedCrossRef
17.
Solomon R, Dauerman HL. Contrast-induced acute kidney injury. Circulation. 2010;122(23):2451–5.PubMedCrossRef
18.
McCullough PA. Radiocontrast-induced acute kidney injury. Nephron Physiol. 2008;109(4):61–72.CrossRef
19.
Reinecke H, Fobker M, Wellmann J, Becke B, Fleiter J, Heitmeyer C, et al. A randomized controlled trial comparing hydration therapy to additional hemodialysis or N-acetylcysteine for the prevention of contrast medium-induced nephropathy: the dialysis-versus-diuresis (DVD) trial. Clin Res Cardiol. 2007;96(3):130–9.PubMedCrossRef
20.
Seeliger E, Sendeski M, Rihal CS, Persson PB. Contrast-induced kidney injury: mechanisms, risk factors, and prevention. Eur Heart J. 2012;33(16):2007–15.PubMedCrossRef
21.
Persson PB, Tepel M. Contrast medium-induced nephropathy: the pathophysiology. Kidney Int Suppl. 2006;100:S8–10.PubMedCrossRef
22.
Hardiek K, Katholi RE, Ramkumar V, Deitrick C. Proximal tubule cell response to radiographic contrast media. Am J Physiol Renal Physiol. 2001;280(1):F61–70.PubMed
23.
Brezis M, Rosen S, Silva P, Epstein FH. Selective vulnerability of the medullary thick ascending limb to anoxia in the isolated perfused rat kidney. J Clin Invest. 1984;73(1):182–90.PubMedPubMedCentralCrossRef
24.
Katzberg RW, Morris TW, Burgener FA, Kamm DE, Fischer HW. Renal renin and hemodynamic responses to selective renal artery catheterization and angiography. Investig Radiol. 1977;12(5):381–8.CrossRef
25.
Katzberg RW, Schulman G, Meggs LG, Caldicott WJ, Damiano MM, Hollenberg NK. Mechanism of the renal response to contrast medium in dogs. Decrease in renal function due to hypertonicity. Investig Radiol. 1983;18(1):74–80.CrossRef
26.
Talner LB, Davidson AJ. Renal hemodynamic effects of contrast media. Investig Radiol. 1968;3(5):310–7.CrossRef
27.
Katholi RE, Taylor GJ, McCann WP, Woods Jr WT, Womack KA, McCoy CD, et al. Nephrotoxicity from contrast media: attenuation with theophylline. Radiology. 1995;195(1):17–22.PubMedCrossRef
28.
Erley CM, Duda SH, Schlepckow S, Koehler J, Huppert PE, Strohmaier WL, et al. Adenosine antagonist theophylline prevents the reduction of glomerular filtration rate after contrast media application. Kidney Int. 1994;45(5):1425–31.PubMedCrossRef
29.
Arend LJ, Bakris GL, Burnett Jr JC, Megerian C, Spielman WS. Role for intrarenal adenosine in the renal hemodynamic response to contrast media. J Lab Clin Med. 1987;110(4):406–11.PubMed
30.
Schnackenberg CG. Physiological and pathophysiological roles of oxygen radicals in the renal microvasculature. Am J Physiol Regul Integr Comp Physiol. 2002;282(2):R335–42.PubMedCrossRef
31.
Liss P, Carlsson PO, Nygren A, Palm F, Hansell P. Et-A receptor antagonist BQ123 prevents radiocontrast media-induced renal medullary hypoxia. Acta Radiol. 2003;44(1):111–7.PubMedCrossRef
32.
Wang A, Holcslaw T, Bashore TM, Freed MI, Miller D, Rudnick MR, et al. Exacerbation of radiocontrast nephrotoxicity by endothelin receptor antagonism. Kidney Int. 2000;57(4):1675–80.PubMedCrossRef
33.
Bakris GL, Lass N, Gaber AO, Jones JD, Burnett Jr JC. Radiocontrast medium-induced declines in renal function: a role for oxygen free radicals. Am J Physiol. 1990;258(1 Pt 2):F115–20.PubMed
34.
Katholi RE, Woods Jr WT, Taylor GJ, Deitrick CL, Womack KA, Katholi CR, et al. Oxygen free radicals and contrast nephropathy. Am J Kidney Dis. 1998;32(1):64–71.PubMedCrossRef
35.
Beeri R, Symon Z, Brezis M, Ben-Sasson SA, Baehr PH, Rosen S, et al. Rapid DNA fragmentation from hypoxia along the thick ascending limb of rat kidneys. Kidney Int. 1995;47(6):1806–10.PubMedCrossRef
36.
McCullough PA. Contrast-induced acute kidney injury. J Am Coll Cardiol. 2008;51(15):1419–28.PubMedCrossRef
37.
Hizoh I, Strater J, Schick CS, Kubler W, Haller C. Radiocontrast-induced DNA fragmentation of renal tubular cells in vitro: role of hypertonicity. Nephrol Dial Transplant. 1998;13(4):911–8.PubMedCrossRef
38.
Ueda J, Nygren A, Hansell P, Erikson U. Influence of contrast media on single nephron glomerular filtration rate in rat kidney. A comparison between diatrizoate, iohexol, ioxaglate, and iotrolan. Acta Radiol. 1992;33(6):596–9.PubMed
39.
Thomsen HS. Guidelines for contrast media from the European Society of Urogenital Radiology. AJR Am J Roentgenol. 2003;181(6):1463–71.PubMedCrossRef
40.
Fliser D, Laville M, Covic A, Fouque D, Vanholder R, Juillard L, et al. A European Renal Best Practice (ERBP) position statement on the Kidney Disease Improving Global Outcomes (KDIGO) clinical practice guidelines on acute kidney injury: part 1: definitions, conservative management and contrast-induced nephropathy. Nephrol Dial Transplant. 2012;27(12):4263–72.PubMedPubMedCentralCrossRef
41.
Solomon R, Deray G. How to prevent contrast-induced nephropathy and manage risk patients: practical recommendations. Kidney Int Suppl. 2006;100:S51–3.PubMedCrossRef
42.
Lakhal K, Ehrmann S, Chaari A, Laissy JP, Regnier B, Wolff M, et al. Acute kidney injury network definition of contrast-induced nephropathy in the critically ill: incidence and outcome. J Crit Care. 2011;26(6):593–9.PubMedCrossRef
43.
Slocum NK, Grossman PM, Moscucci M, Smith DE, Aronow HD, Dixon SR, et al. The changing definition of contrast-induced nephropathy and its clinical implications: insights from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2). Am Heart J. 2012;163(5):829–34.PubMedCrossRef
44.
Marenzi G, Lauri G, Assanelli E, Campodonico J, De Metrio M, Marana I, et al. Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction. J Am Coll Cardiol. 2004;44(9):1780–5.PubMedCrossRef
45.
Mehran R, Aymong ED, Nikolsky E, Lasic Z, Iakovou I, Fahy M, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol. 2004;44(7):1393–9.PubMed
46.
Iakovou I, Dangas G, Mehran R, Lansky AJ, Ashby DT, Fahy M, et al. Impact of gender on the incidence and outcome of contrast-induced nephropathy after percutaneous coronary intervention. J Invasive Cardiol. 2003;15(1):18–22.PubMed
47.
Budano C, Levis M, D'Amico M, Usmiani T, Fava A, Sbarra P, et al. Impact of contrast-induced acute kidney injury definition on clinical outcomes. Am Heart J. 2011;161(5):963–71.PubMedCrossRef
48.
Caruso M, Balasus F, Incalcaterra E, Ruggieri A, Evola S, Fattouch K, et al. Contrast-induced nephropathy after percutaneous coronary intervention in simple lesions: risk factors and incidence are affected by the definition utilized. Intern Med. 2011;50(9):983–9.PubMedCrossRef
49.
Chousterman BG, Bouadma L, Moutereau S, Loric S, Alvarez-Gonzalez A, Mekontso-Dessap A, et al. Prevention of contrast-induced nephropathy by N-acetylcysteine in critically ill patients: different definitions, different results. J Crit Care. 2013;28(5):701–9.PubMedCrossRef
50.
Sinert R, Brandler E, Subramanian RA, Miller AC. Does the current definition of contrast-induced acute kidney injury reflect a true clinical entity? Acad Emerg Med. 2012;19(11):1261–7.PubMedCrossRef
51.
Caixeta A, Mehran R. Evidence-based management of patients undergoing PCI: contrast-induced acute kidney injury. Catheter Cardiovasc Interv. 2010;75 Suppl 1:S15–20.PubMedCrossRef
52.
Chiou WL, Hsu FH. Pharmacokinetics of creatinine in man and its implications in the monitoring of renal function and in dosage regimen modifications in patients with renal insufficiency. J Clin Pharmacol. 1975;15(5-6):427–34.PubMedCrossRef
53.
Moran SM, Myers BD. Course of acute renal failure studied by a model of creatinine kinetics. Kidney Int. 1985;27(6):928–37.PubMedCrossRef
54.
55.
Lin J, Fernandez H, Shashaty MG, Negoianu D, Testani JM, Berns JS et al. False-Positive Rate of AKI Using Consensus Creatinine-Based Criteria. Clin J Am Soc Nephrol. 2015
56.
Briguori C, Quintavalle C, Donnarumma E, Condorelli G. Novel biomarkers for contrast-induced acute kidney injury. Biomed Res Int. 2014;2014:568738.PubMedPubMedCentralCrossRef
57.
58.
Stacul F, van der Molen AJ, Reimer P, Webb JA, Thomsen HS, Morcos SK, et al. Contrast induced nephropathy: updated ESUR contrast media safety committee guidelines. Eur Radiol. 2011;21(12):2527–41.PubMedCrossRef
59.
Marenzi G, Assanelli E, Campodonico J, Lauri G, Marana I, De Metrio M, et al. Contrast volume during primary percutaneous coronary intervention and subsequent contrast-induced nephropathy and mortality. Ann Intern Med. 2009;150(3):170–7.PubMedCrossRef
60.
Kane GC, Doyle BJ, Lerman A, Barsness GW, Best PJ, Rihal CS. Ultra-low contrast volumes reduce rates of contrast-induced nephropathy in patients with chronic kidney disease undergoing coronary angiography. J Am Coll Cardiol. 2008;51(1):89–90.PubMedCrossRef
61.
Owen RJ, Hiremath S, Myers A, Fraser-Hill M, Barrett BJ. Canadian association of radiologists consensus guidelines for the prevention of contrast-induced nephropathy: update 2012. Can Assoc Radiol J. 2014;65(2):96–105.PubMedCrossRef
62.
Keaney JJ, Hannon CM, Murray PT. Contrast-induced acute kidney injury: how much contrast is safe? Nephrol Dial Transplant. 2013;28(6):1376–83.PubMedCrossRef
63.
Cigarroa RG, Lange RA, Williams RH, Hillis LD. Dosing of contrast material to prevent contrast nephropathy in patients with renal disease. Am J Med. 1989;86(6 Pt 1):649–52.PubMedCrossRef
64.
Freeman RV, O'Donnell M, Share D, Meengs WL, Kline-Rogers E, Clark VL, et al. Nephropathy requiring dialysis after percutaneous coronary intervention and the critical role of an adjusted contrast dose. Am J Cardiol. 2002;90(10):1068–73.PubMedCrossRef
65.
Mager A, Vaknin Assa H, Lev EI, Bental T, Assali A, Kornowski R. The ratio of contrast volume to glomerular filtration rate predicts outcomes after percutaneous coronary intervention for ST-segment elevation acute myocardial infarction. Catheter Cardiovasc Interv. 2011;78(2):198–201.PubMedCrossRef
66.
Gurm HS, Dixon SR, Smith DE, Share D, Lalonde T, Greenbaum A, et al. Renal function-based contrast dosing to define safe limits of radiographic contrast media in patients undergoing percutaneous coronary interventions. J Am Coll Cardiol. 2011;58(9):907–14.PubMedCrossRef
67.
Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014;35(37):2541–619.PubMedCrossRef
68.
Park HS, Kim CJ, Yi JE, Hwang BH, Kim TH, Koh YS, et al. Contrast volume/Raw eGFR ratio for predicting contrast-induced acute kidney injury in patients undergoing percutaneous coronary intervention for myocardial infarction. Cardiorenal Med. 2015;5(1):61–8.PubMedPubMedCentralCrossRef
69.
Yoon HJ, Hur SH. Determination of safe contrast media dosage to estimated glomerular filtration rate ratios to avoid contrast-induced nephropathy after elective percutaneous coronary intervention. Korean Circ J. 2011;41(5):265–71.PubMedPubMedCentralCrossRef
70.
Nyman U, Bjork J, Aspelin P, Marenzi G. Contrast medium dose-to-GFR ratio: a measure of systemic exposure to predict contrast-induced nephropathy after percutaneous coronary intervention. Acta Radiol. 2008;49(6):658–67.PubMedCrossRef
71.
Azzalini L, Spagnoli V, Ly HQ. Contrast-Induced Nephropathy: From Pathophysiology to Preventive Strategies. Can J Cardiol. 2015
72.
Tepel M, Aspelin P, Lameire N. Contrast-induced nephropathy: a clinical and evidence-based approach. Circulation. 2006;113(14):1799–806.PubMedCrossRef
73.
Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP. Contrast-induced nephropathy: an "All or none" phenomenon? Angiology. 2015;66(6):508–13.PubMedCrossRef
74.
Ohno Y, Maekawa Y, Miyata H, Inoue S, Ishikawa S, Sueyoshi K, et al. Impact of periprocedural bleeding on incidence of contrast-induced acute kidney injury in patients treated with percutaneous coronary intervention. J Am Coll Cardiol. 2013;62(14):1260–6.PubMedCrossRef
75.
Wi J, Ko YG, Kim JS, Kim BK, Choi D, Ha JW, et al. Impact of contrast-induced acute kidney injury with transient or persistent renal dysfunction on long-term outcomes of patients with acute myocardial infarction undergoing percutaneous coronary intervention. Heart. 2011;97(21):1753–7.PubMedCrossRef
76.
Mitchell AM, Kline JA, Jones AE, Tumlin JA. Major Adverse Events One Year After Acute Kidney Injury After Contrast-Enhanced Computed Tomography. Ann Emerg Med. 2015.
77.
James MT, Samuel SM, Manning MA, Tonelli M, Ghali WA, Faris P, et al. Contrast-induced acute kidney injury and risk of adverse clinical outcomes after coronary angiography: a systematic review and meta-analysis. Circ Cardiovasc Interv. 2013;6(1):37–43.PubMedCrossRef
78.
Dangas G, Iakovou I, Nikolsky E, Aymong ED, Mintz GS, Kipshidze NN, et al. Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables. Am J Cardiol. 2005;95(1):13–9.PubMedCrossRef
79.
Kini AS, Sarkar K, Rafael OC, Jakkula M, Kaplish D, Lee P, et al. Serum creatinine ratio: a novel predictor of mortality after percutaneous coronary intervention in patients with normal and abnormal renal function. Catheter Cardiovasc Interv. 2009;74(1):49–55.PubMedCrossRef
80.
Weisbord SD, Chen H, Stone RA, Kip KE, Fine MJ, Saul MI, et al. Associations of increases in serum creatinine with mortality and length of hospital stay after coronary angiography. J Am Soc Nephrol. 2006;17(10):2871–7.PubMedCrossRef
81.
Abe M, Morimoto T, Akao M, Furukawa Y, Nakagawa Y, Shizuta S, et al. Relation of contrast-induced nephropathy to long-term mortality after percutaneous coronary intervention. Am J Cardiol. 2014;114(3):362–8.PubMedCrossRef
82.
Chen SL, Zhang J, Yei F, Zhu Z, Liu Z, Lin S, et al. Clinical outcomes of contrast-induced nephropathy in patients undergoing percutaneous coronary intervention: a prospective, multicenter, randomized study to analyze the effect of hydration and acetylcysteine. Int J Cardiol. 2008;126(3):407–13.PubMedCrossRef
83.
Wickenbrock I, Perings C, Maagh P, Quack I, van Bracht M, Prull MW, et al. Contrast medium induced nephropathy in patients undergoing percutaneous coronary intervention for acute coronary syndrome: differences in STEMI and NSTEMI. Clin Res Cardiol. 2009;98(12):765–72.PubMedCrossRef
84.
Weisbord SD, Hartwig KC, Sonel AF, Fine MJ, Palevsky P. The incidence of clinically significant contrast-induced nephropathy following non-emergent coronary angiography. Catheter Cardiovasc Interv. 2008;71(7):879–85.PubMedCrossRef
85.
Gruberg L, Mintz GS, Mehran R, Gangas G, Lansky AJ, Kent KM, et al. The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existent chronic renal insufficiency. J Am Coll Cardiol. 2000;36(5):1542–8.PubMedCrossRef
86.
Nemoto N, Iwasaki M, Nakanishi M, Araki T, Utsunomiya M, Hori M, et al. Impact of continuous deterioration of kidney function 6 to 8 months after percutaneous coronary intervention for acute coronary syndrome. Am J Cardiol. 2014;113(10):1647–51.PubMedCrossRef
87.
Abaci O, Harmankaya O, Kocas B, Kocas C, Bostan C, Coskun U, et al. Long-term follow-Up of patients at high risk for nephropathy after contrast exposure. Angiology. 2015;66(6):514–8.PubMedCrossRef
88.
Holscher B, Heitmeyer C, Fobker M, Breithardt G, Schaefer RM, Reinecke H. Predictors for contrast media-induced nephropathy and long-term survival: prospectively assessed data from the randomized controlled Dialysis-Versus-Diuresis (DVD) trial. Can J Cardiol. 2008;24(11):845–50.PubMedPubMedCentralCrossRef
89.
Bartholomew BA, Harjai KJ, Dukkipati S, Boura JA, Yerkey MW, Glazier S, et al. Impact of nephropathy after percutaneous coronary intervention and a method for risk stratification. Am J Cardiol. 2004;93(12):1515–9.PubMedCrossRef
90.
Tziakas D, Chalikias G, Stakos D, Apostolakis S, Adina T, Kikas P, et al. Development of an easily applicable risk score model for contrast-induced nephropathy prediction after percutaneous coronary intervention: a novel approach tailored to current practice. Int J Cardiol. 2013;163(1):46–55.PubMedCrossRef
91.
Tziakas D, Chalikias G, Stakos D, Altun A, Sivri N, Yetkin E, et al. Validation of a new risk score to predict contrast-induced nephropathy after percutaneous coronary intervention. Am J Cardiol. 2014;113(9):1487–93.PubMedCrossRef
92.
Silver SA, Shah PM, Chertow GM, Harel S, Wald R, Harel Z. Risk prediction models for contrast induced nephropathy: systematic review. BMJ. 2015;351:h4395.PubMedPubMedCentralCrossRef
93.
Tziakas D, Chalikias G, Kareli D, Tsigalou C, Risgits A, Kikas P, et al. Spot urine albumin to creatinine ratio outperforms novel acute kidney injury biomarkers in patients with acute myocardial infarction. Int J Cardiol. 2015;197:48–55.PubMedCrossRef
94.
Haase M, Bellomo R, Devarajan P, Schlattmann P, Haase-Fielitz A. Accuracy of neutrophil gelatinase-associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: a systematic review and meta-analysis. Am J Kidney Dis. 2009;54(6):1012–24.PubMedCrossRef
95.
Shlipak MG, Matsushita K, Arnlov J, Inker LA, Katz R, Polkinghorne KR, et al. Cystatin C versus creatinine in determining risk based on kidney function. N Engl J Med. 2013;369(10):932–43.PubMedPubMedCentralCrossRef
96.
Liu Y, Guo W, Zhang J, Xu C, Yu S, Mao Z, et al. Urinary interleukin 18 for detection of acute kidney injury: a meta-analysis. Am J Kidney Dis. 2013;62(6):1058–67.PubMedCrossRef
97.
Lin X, Yuan J, Zhao Y, Zha Y. Urine interleukin-18 in prediction of acute kidney injury: a systemic review and meta-analysis. Am J Nephrol. 2015;28(1):7–16.CrossRef
98.
Molitoris BA. Urinary biomarkers: alone Are they enough? J Am Soc Nephrol. 2015;26(7):1485–8.PubMedCrossRef
99.
Morcos SK, Thomsen HS, Webb JA. Contrast-media-induced nephrotoxicity: a consensus report. Contrast media safety committee, european society of urogenital radiology (ESUR). Eur Radiol. 1999;9(8):1602–13.PubMedCrossRef
100.
101.
Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO clinical practice guideline for acute kidney injury. Kidney inter. 2012;2(1):1.CrossRef
102.
Jorres A, John S, Lewington A, ter Wee PM, Vanholder R, Van Biesen W, et al. A European Renal Best Practice (ERBP) position statement on the Kidney Disease Improving Global Outcomes (KDIGO) Clinical Practice Guidelines on Acute Kidney Injury: part 2: renal replacement therapy. Nephrol Dial Transplant. 2013;28(12):2940–5.PubMedCrossRef
103.
104.
Gupta R, Gurm HS, Bhatt DL, Chew DP, Ellis SG. Renal failure after percutaneous coronary intervention is associated with high mortality. Catheter Cardiovasc Interv. 2005;64(4):442–8.PubMedCrossRef
105.
Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care. 2007;11(2):R31.PubMedPubMedCentralCrossRef
106.
Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care. 2004;8(4):R204–12.PubMedPubMedCentralCrossRef
107.
Harjai KJ, Raizada A, Shenoy C, Sattur S, Orshaw P, Yaeger K, et al. A comparison of contemporary definitions of contrast nephropathy in patients undergoing percutaneous coronary intervention and a proposal for a novel nephropathy grading system. Am J Cardiol. 2008;101(6):812–9.PubMedCrossRef
108.
Watabe H, Sato A, Hoshi T, Takeyasu N, Abe D, Akiyama D, et al. Association of contrast-induced acute kidney injury with long-term cardiovascular events in acute coronary syndrome patients with chronic kidney disease undergoing emergent percutaneous coronary intervention. Int J Cardiol. 2014;174(1):57–63.PubMedCrossRef
109.
Jabara R, Gadesam RR, Pendyala LK, Knopf WD, Chronos N, Chen JP, et al. Impact of the definition utilized on the rate of contrast-induced nephropathy in percutaneous coronary intervention. Am J Cardiol. 2009;103(12):1657–62.PubMedCrossRef
110.
Goldenberg I, Chonchol M, Guetta V. Reversible acute kidney injury following contrast exposure and the risk of long-term mortality. Am J Nephrol. 2009;29(2):136–44.PubMedCrossRef
111.
Roy P, Raya V, Okabe T, Pinto Slottow TL, Steinberg DH, Smith K, et al. Incidence, predictors, and outcomes of post-percutaneous coronary intervention nephropathy in patients with diabetes mellitus and normal baseline serum creatinine levels. Am J Cardiol. 2008;101(11):1544–9.PubMedCrossRef
112.
Cho JY, Jeong MH, Hwan Park S, Kim IS, Park KH, Sim DS, et al. Effect of contrast-induced nephropathy on cardiac outcomes after use of nonionic isosmolar contrast media during coronary procedure. J Cardiol. 2010;56(3):300–6.PubMedCrossRef
113.
Kume K, Yasuoka Y, Adachi H, Noda Y, Hattori S, Araki R, et al. Impact of contrast-induced acute kidney injury on outcomes in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Cardiovasc Revasc Med. 2013;14(5):253–7.PubMedCrossRef
114.
Narula A, Mehran R, Weisz G, Dangas GD, Yu J, Genereux P, et al. Contrast-induced acute kidney injury after primary percutaneous coronary intervention: results from the HORIZONS-AMI substudy. Eur Heart J. 2014;35(23):1533–40.PubMedCrossRef
115.
Patti G, Nusca A, Chello M, Pasceri V, D'Ambrosio A, Vetrovec GW, et al. Usefulness of statin pretreatment to prevent contrast-induced nephropathy and to improve long-term outcome in patients undergoing percutaneous coronary intervention. Am J Cardiol. 2008;101(3):279–85.PubMedCrossRef
116.
Kim JH, Yang JH, Choi SH, Song YB, Hahn JY, Choi JH, et al. Predictors of outcomes of contrast-induced acute kidney injury after percutaneous coronary intervention in patients with chronic kidney disease. Am J Cardiol. 2014;114(12):1830–5.PubMedCrossRef
117.
Crimi G, Leonardi S, Costa F, Ariotti S, Tebaldi M, Biscaglia S, et al. Incidence, prognostic impact, and optimal definition of contrast-induced acute kidney injury in consecutive patients with stable or unstable coronary artery disease undergoing percutaneous coronary intervention. insights from the all-comer PRODIGY trial. Catheter Cardiovasc Interv. 2015;86(1):E19–27.PubMedCrossRef
118.
Senoo T, Motohiro M, Kamihata H, Yamamoto S, Isono T, Manabe K, et al. Contrast-induced nephropathy in patients undergoing emergency percutaneous coronary intervention for acute coronary syndrome. Am J Cardiol. 2010;105(5):624–8.PubMedCrossRef
119.
Coca SG, Yalavarthy R, Concato J, Parikh CR. Biomarkers for the diagnosis and risk stratification of acute kidney injury: a systematic review. Kidney Int. 2008;73(9):1008–16.PubMedCrossRef
120.
McCullough PA, Tumlin J, Szerlip H, Krishnaswami V, Jyothinagaram S, Rausch JF et al. Cardiorenal Syndromes: Advances in Determining Diagnosis, Prognosis and Therapy. J Cardiovasc Dis Diagn. 2015;3(221)
Metadaten
Titel
Contrast-Induced Acute Kidney Injury: An Update
verfasst von
George Chalikias
Ioannis Drosos
Dimitrios N. Tziakas
Publikationsdatum
16.01.2016
Verlag
Springer US
Erschienen in
Cardiovascular Drugs and Therapy / Ausgabe 2/2016
Print ISSN: 0920-3206
Elektronische ISSN: 1573-7241
DOI
https://doi.org/10.1007/s10557-015-6635-0

Weitere Artikel der Ausgabe 2/2016

Cardiovascular Drugs and Therapy 2/2016 Zur Ausgabe

ORIGINAL ARTICLE

ACE-Inhibition Benefit on Lung Function in Heart Failure is Modulated by ACE Insertion/Deletion Polymorphism

SHORT COMMUNICATION

Cangrelor-Mediated Cardioprotection Requires Platelets and Sphingosine Phosphorylation

ORIGINAL ARTICLE

Clinical Significance of Laboratory-determined Aspirin Poor Responsiveness After Primary Percutaneous Coronary Intervention

ORIGINAL ARTICLE

Design and Rationale for the Endothelin-1 Receptor Antagonism in the Prevention of Microvascular Injury in Patients with non-ST Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention (ENDORA-PCI) Trial

ORIGINAL ARTICLE

A Moderate Carnitine Deficiency Exacerbates Isoproterenol-Induced Myocardial Injury in Rats

REVIEW ARTICLE

Lipophilic Statin Versus Rosuvastatin (Hydrophilic) Treatment for Heart Failure: a Meta-Analysis and Adjusted Indirect Comparison of Randomised Trials

Neu im Fachgebiet Kardiologie

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

10.05.2024 Hypercholesterinämie Nachrichten

Patienten mit Arteriosklerose-bedingten kardiovaskulären Erkrankungen, die trotz Statineinnahme zu hohe Triglyzeridspiegel haben, profitieren von einer Behandlung mit Icosapent-Ethyl, und zwar unabhängig vom individuellen Risikoprofil.

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

10.05.2024 Periphere arterielle Verschlusskrankheit Nachrichten

In den USA ist erstmals eine bioresorbierbare Gefäßstütze – auch Scaffold genannt – zur Rekanalisation infrapoplitealer Arterien bei schwerer PAVK zugelassen worden. Das markiert einen Wendepunkt in der Geschichte dieser speziellen Gefäßstützen.

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise